About Prodelics

Pioneering the Future of Neuro-Therapeutic Drug Delivery

At Prodelics, our mission is to accelerate the global mass adoption of next-generation neuroplastic and psychedelic-assisted therapies. We operate at the intersection of formulation science, clinical economics, and intellectual property strategy to solve the most critical bottlenecks standing between breakthrough molecular research and scalable, real-world patient care.

We do not discover new molecules. Instead, we re-engineer how they are delivered.

The Bottlenecks We Solve

While early-phase clinical trials continue to validate the remarkable neuropsychiatric efficacy of classic serotonergic agonists and entactogens, the transition to mainstream medical infrastructure is hindered by severe physical and operational challenges.

The In-Clinic Scaling Crisis: Traditional oral administration often results in protracted subjective experiences lasting anywhere from 6 to 12 hours. This requires intensive, resource-heavy monitoring in specialized clinics by multiple certified healthcare providers, inflating treatment costs and severely limiting patient throughput.
Erratic Pharmacokinetic Profiles: Oral delivery exposes highly sensitive, lipophilic compounds to immediate enzymatic degradation in the gastrointestinal tract and first-pass hepatic metabolism. The result is poor bioavailability, slow and delayed onset times, and significant patient-to-patient plasma variability.
The Intellectual Property Barrier: Because first-generation neuro-active molecules reside in the public domain, clinical drug sponsors cannot easily protect their underlying assets. Securing defensible, long-term commercial viability requires advanced, formulation-based patent protection.

Our Advanced Delivery Modalities

Prodelics designs and optimizes physical drug delivery systems that bypass hepatic metabolism, enable precise temporal control, and minimize side effects.

1. Fast-Dissolving Transmucosal Films
Designed for buccal and sublingual application, our fast-dissolving transmucosal thin films leverage the highly vascularized oral mucosa. This route delivers therapeutic compounds directly into systemic circulation. By bypassing the stomach and the liver, this modality provides a rapid therapeutic onset while minimizing gastrointestinal side effects such as nausea.

2. Intranasal Self-Nanoemulsifying Systems (SNEDDS)
Our nanotechnology-based lipid carriers and smart intranasal sprays spontaneously emulsify upon contact with nasal mucosal fluids. This platform optimizes nose-to-brain transport pathways, dramatically improving central bioavailability while avoiding systemic absorption spikes to ensure more predictable, smoothed, and safe concentration-time curves.

3. Dissolving Hydrogel Microneedle Patches
Our transdermal product platform utilizes biodegradable and biocompatible hydrogel microneedle arrays. These tiny projections physically breach the skin's outer barrier (the stratum corneum) painlessly and without contacting nerve endings. Once inserted, they absorb fluid and swell to create sustained, zero-order controlled release channels, allowing for highly customizable dosing kinetics.

Advancing Toward Mass Adoption

Every delivery platform developed by Prodelics is engineered to meet the concrete operational and economic realities of global healthcare networks:

Temporal Compression: By employing rapid-onset, rapid-offset delivery routes like buccal films and optimized intranasal sprays, we compress active treatment sessions to fit comfortably within the industry-standard two-hour interventional psychiatry monitoring window. This aligns treatments with existing clinic billing workflows and dramatically increases patient throughput.
Decentralized Outpatient Care: For chronic, somatic, or non-hallucinogenic applications, our extended-release transdermal patches and microneedle arrays allow for sustained, low-dose therapeutic delivery. This enables a shift away from intensive clinic-based supervision toward safe, monitored, and convenient at-home care.
Clinical & Commercial De-risking: We provide clinical-stage biopharmaceutical partners with a highly defensible intellectual property moat. By pairing public-domain therapeutics with proprietary, patent-protected physical matrices and device platforms, we help sponsors secure investments, accelerate regulatory timelines, and extend commercial exclusivity.

Our Partner Model

Prodelics operates as a collaborative B2B innovation partner. We work alongside clinical-stage biotech developers, compounding pharmacies, and contract development and manufacturing organizations (CDMOs). By delivering pre-optimized, technically rigorous formulation templates and delivery hardware, we help our partners de-risk their pipelines long before initiating high-cost active clinical trials.